Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 10/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3766417 | 0.87 | FAAH (0.61) | FAAHTRPV1GRIN2BNPC1RAB9A | |
| SCHEMBL3774294 | 0.86 | TRPV1 (0.54) | FAAHTRPV1GRIN2BSMN1; SMN2 | |
| SCHEMBL3765809 | 0.84 | TRPV1 (0.53) | FAAHTRPV1NPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3771939 | 0.83 | FAAH (0.63) | FAAHTRPV1NPC1RAB9ATDP1 | |
| Hydrochloric Acid SCHEMBL3771784 | 0.83 | TRPV1 (0.53) | FAAHTRPV1NPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3770630 | 0.80 | NPC1 (0.52) | FAAHNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3767493 | 0.78 | FAAH (0.54) | FAAHNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16391926 | 0.77 | TRPV1 (0.56) | FAAHTRPV1NPC1RAB9ATDP1 | |
| SCHEMBL3765881 | 0.76 | FAAH (0.54) | FAAHTRPV1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13294783 | 0.75 | FAAH (0.44) | FAAHTRPV1GRIN2BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | FAAH 1/4885TRPV1 87/4885GRIN2B 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.